Cargando…

CD206(+) tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity

In many solid cancers, tumor-associated macrophages (TAM) represent the predominant myeloid cell population. Antigen (Ag) cross-presentation leading to tumor Ag–directed cytotoxic CD8(+) T cell responses is crucial for antitumor immunity. However, the role of recruited monocyte-derived macrophages,...

Descripción completa

Detalles Bibliográficos
Autores principales: Modak, Madhura, Mattes, Ann-Kathrin, Reiss, Daniela, Skronska-Wasek, Wioletta, Langlois, Rebecca, Sabarth, Nicolas, Konopitzky, Renate, Ramirez, Fidel, Lehr, Katharina, Mayr, Tobias, Kind, David, Viollet, Coralie, Swee, Lee Kim, Petschenka, Jutta, El Kasmi, Karim C., Noessner, Elfriede, Kitt, Kerstin, Pflanz, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220841/
https://www.ncbi.nlm.nih.gov/pubmed/35503656
http://dx.doi.org/10.1172/jci.insight.155022
Descripción
Sumario:In many solid cancers, tumor-associated macrophages (TAM) represent the predominant myeloid cell population. Antigen (Ag) cross-presentation leading to tumor Ag–directed cytotoxic CD8(+) T cell responses is crucial for antitumor immunity. However, the role of recruited monocyte-derived macrophages, including TAM, as potential cross-presenting cells is not well understood. Here, we show that primary human as well as mouse CD206(+) macrophages are effective in functional cross-presentation of soluble self-Ag and non–self-Ag, including tumor-associated Ag (TAA), as well as viral Ag. To confirm the presence of cross-presenting TAM in vivo, we performed phenotypic and functional analysis of TAM from B16-F10 and CT26 syngeneic tumor models and have identified CD11b+F4/80hiCD206+ TAM to effectively cross-present TAA. We show that CD11b+CD206+ TAM represent the dominant tumor-infiltrating myeloid cell population, expressing a unique cell surface repertoire, promoting Ag cross-presentation and Ag-specific CD8+ T cell activation comparable with cross-presenting CLEC9A+ DCs (cDC1). The presence of cross-presenting CD206+ TAM is associated with reduced tumor burden in mouse syngeneic tumor models and with improved overall survival in cutaneous melanoma patients. Therefore, the demonstration of effective Ag cross-presentation capabilities of CD206+ TAM, including their clinical relevance, expands our understanding of TAM phenotypic diversity and functional versatility.